1. Home
  2. KNSA vs HUBG Comparison

KNSA vs HUBG Comparison

Compare KNSA & HUBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • HUBG
  • Stock Information
  • Founded
  • KNSA 2015
  • HUBG 1971
  • Country
  • KNSA United Kingdom
  • HUBG United States
  • Employees
  • KNSA N/A
  • HUBG N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • HUBG Oil Refining/Marketing
  • Sector
  • KNSA Health Care
  • HUBG Consumer Discretionary
  • Exchange
  • KNSA Nasdaq
  • HUBG Nasdaq
  • Market Cap
  • KNSA 2.6B
  • HUBG 2.2B
  • IPO Year
  • KNSA 2018
  • HUBG 1996
  • Fundamental
  • Price
  • KNSA $35.92
  • HUBG $37.14
  • Analyst Decision
  • KNSA Strong Buy
  • HUBG Buy
  • Analyst Count
  • KNSA 6
  • HUBG 8
  • Target Price
  • KNSA $40.83
  • HUBG $41.89
  • AVG Volume (30 Days)
  • KNSA 392.6K
  • HUBG 638.1K
  • Earning Date
  • KNSA 10-28-2025
  • HUBG 10-29-2025
  • Dividend Yield
  • KNSA N/A
  • HUBG 1.35%
  • EPS Growth
  • KNSA N/A
  • HUBG N/A
  • EPS
  • KNSA 0.07
  • HUBG 1.65
  • Revenue
  • KNSA $529,332,000.00
  • HUBG $3,781,266,000.00
  • Revenue This Year
  • KNSA $37.21
  • HUBG N/A
  • Revenue Next Year
  • KNSA $11.99
  • HUBG $6.02
  • P/E Ratio
  • KNSA $542.28
  • HUBG $22.42
  • Revenue Growth
  • KNSA 56.18
  • HUBG N/A
  • 52 Week Low
  • KNSA $17.82
  • HUBG $30.75
  • 52 Week High
  • KNSA $37.34
  • HUBG $53.21
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 60.14
  • HUBG 53.61
  • Support Level
  • KNSA $35.29
  • HUBG $36.46
  • Resistance Level
  • KNSA $37.34
  • HUBG $38.18
  • Average True Range (ATR)
  • KNSA 1.00
  • HUBG 1.09
  • MACD
  • KNSA -0.15
  • HUBG -0.06
  • Stochastic Oscillator
  • KNSA 65.30
  • HUBG 59.18

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

About HUBG Hub Group Inc.

Hub Group ranks among the largest providers of rail intermodal service. Roughly 60% of consolidated revenue comes from Hub's intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload shipping unit. Hub's logistics segment includes its asset-light truck brokerage operations along with its outsourced transportation management, warehousing and fulfillment, and heavy-goods final mile delivery offerings. Hub often makes tuck-in acquisitions that expand its brokerage, last-mile, and dedicated offerings.

Share on Social Networks: